Development of Abelmoschus esculentus (Okra)-Based Mucoadhesive Gel for Nasal Delivery of Rizatriptan Benzoate

Sharma, Nitin; Kulkarni, Giriraj T.; Sharma, Anjana

doi:10.4314/tjpr.v12i2.3

Cited by 16 publications

(11 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The temperature was regulated using pettier thermo regulatory (Brookfield PTR-I) and obtained data was recorded with the help of software RHEO 2000 version 2.5. 24 Nasal formulation (1 mL) was placed in measuring the gap between the rotating cone and the stationary lower plate and allowed to equilibrate for 5-10 min at 37±0.5°C. Apparent viscosity was measured at 10 shear rate (s -1 ).…”

Section: Viscositymentioning

confidence: 99%

Intranasal Nalbuphine Formulation for Faster Management of Pain in Prehospital Scenario; Its Safety and Comparative Efficacy in Animal Models

Khanna¹,

Sharma²,

Karwasra³

et al. 2020

IJPER

View full text Add to dashboard Cite

Aim: Nalbuphine (NLB) is an approved opioid analgesic for the management of severe pain in wounds, battlefield injuries and is recommended to subsidize labour pain during childbirth. The study aims to develop an intranasal opioid formulation for faster pain relief. Secondly to avoid patient inconvenience and make it available for buddy care. In case of war, accident or any natural calamities the feasibility of giving drugs from the parenteral route is not feasible as it requires high skilled medic/paramedic staff. Materials and Methods: Different formulations were made using NLB as an Active Pharmaceutical Ingredient (API), prepared formulations (F1-F10) were characterized and evaluated for various parameters. The formulation F5 was optimized as it met the desired criteria. F5 was further studied for its efficacy in an established pain model using Eddy's hot plate method and pain scoring in animals. Pharmacodynamics study was conducted in Sprague dawley rats which were further verified by gamma scintigraphy using 99m Tc-pertechnetate labelled NLB showing significant and rapid deposition in the brain tissue. Results: NLB nasal formulation was optimized successfully; at pH 6.4±0.10 and viscosity 2.5±0.13 (cps). Osmolarity and percent drug release of optimized nasal drop at 240 min was found to be 288±18 milliosmol/litre and 96.98±3.1% respectively. Gamma scintigraphy study results revealed that the formulation (F5) was able to deliver NLB to the brain within 10 mins of administration and remained localized up to 240 min. Pre-clinical subacute toxicity profiling of optimized formulation was done in Sprague dawley rats at 3X dose. Conclusion: Data obtained from the study indicate that the developed NLB nasal formulation has better efficacy for pain management than conventional I.M injection.

show abstract

Section: Viscositymentioning

confidence: 99%

Intranasal Nalbuphine Formulation for Faster Management of Pain in Prehospital Scenario; Its Safety and Comparative Efficacy in Animal Models

Khanna¹,

Sharma²,

Karwasra³

et al. 2020

IJPER

View full text Add to dashboard Cite

show abstract

“…The reading was taken from the scale and converted to kg (10 mm being equivalent to 10 -3 kg as specified on the instrument). The adhesive strength of each dispersion was calculated using the modified form of the equation of Sharma et al [24].…”

Section: Determination Of Adhesive Strengthmentioning

confidence: 99%

Effect of polymer ratio on the quality of a co-processed excipient of prosopis gum and crab shell chitosan

Olorunsola¹,

Usungurua²

2018

Trop. J. Pharm Res

View full text Add to dashboard Cite

Purpose: To assess the effect of polymer ratio on the quality of a novel co-processed excipient of prosopis gum and crab shell chitosan. Methods: The physicochemical properties (DSC thermogram, powder flow properties, porosity and swelling index as well as pH, viscosity and adhesive strength of 2 % w⁄v dispersions) of prosopis gum, chitosan and the three grades of co-processed excipient of prosopis gum and crab shell chitosan (Prosochit® 201, Prosochit® 101 and Prosochit® 102) were determined. Results: The three grades of the co-processed excipient of prosopis gum and crab shell chitosan (Prosochit®) were characterized by one endothermic transition each with peaks at 180 o C, 179 o C and 178 o C for Prosochit®201, Prosochit®101 and Prosochit®102 respectively. Flow properties increased with increase in proportion of chitosan. The porosity of the three grades of the new excipient was not significantly different from that of prosopis gum. Swelling indices of prosopis gum, chitosan, Prosochit® 201, Prosochit® 101 and Prosochit® 102 were 1135.53%, 14.00%, 726.33%, 677.33% and 514.00% respectively. The viscosity also decreased with increase in the proportion of chitosan. The new excipient had higher adhesive strength compared to the individual constituents (prosopis gum and crab shell chitosan). Conclusion: Prosochit® is superior to its individual constituents as a tableting excipient but its suitability for liquid formulation is reduced by increase in the proportion of chitosan.

show abstract

“…Drug permeation study was performed using the method described by Sharma et al (2013). The segments of the small intestine were used as donor chambers.…”

Section: Ex-vivo Permeation Studymentioning

confidence: 99%

Ex-vivo evaluation of crab shell chitosan as absorption enhancer in ciprofloxacin tablet formulation

Olorunsola¹,

Uwah²,

Olayemi³

et al. 2016

Afr. J. Biotechnol.

View full text Add to dashboard Cite

This study was aimed at evaluating crab shell chitosan as absorption enhancer in ciprofloxacin tablet formulation using the ex-vivo model. Six batches of ciprofloxacin tablets containing varying concentrations of crab shell-derived chitosan ranging from 0 to 5% w /w at 1% w /w intervals were produced. Batch CTS-0 containing no chitosan served as the control. The crushing strength, friability, disintegration time, dissolution profile and permeation profile of all the batches were determined. Friability was not significantly affected but the crushing strength and disintegration time of tablets decreased with increase in concentration of chitosan. There was no significant difference in the cumulative percent drug released in 1 h but the cumulative percent drug permeated in 4 h increased with increase in the concentration of chitosan. It increased from 68% (when no chitosan was added) to 81.8% (when 5% w /w chitosan was incorporated). The polymer caused a faster onset of drug release but the eventual total drug released was not significantly influenced. It also improved the permeation of the released drug. This study correlates with in-vivo bioavailability study because the usual oral bioavailability of ciprofloxacin without absorption enhancer is 70%. Hence, crab shell chitosan at concentration of 5% w /w could increase the absorption of ciprofloxacin from 70 to 82%. The study suggests the use of the chitosan at this concentration to improve the absorption of ciprofloxacin.

show abstract

Development of Abelmoschus esculentus (Okra)-Based Mucoadhesive Gel for Nasal Delivery of Rizatriptan Benzoate

Abstract: HPMC and NaCMC was 134.8, 120.9 and 84.8, respectively. Conclusion: Okra mucilage is a promising natural and safe gel former that can be developed to serve as an alternative to currently used synthetic gel formers for nasal drug delivery.

Cited by 16 publications

References 11 publications

Intranasal Nalbuphine Formulation for Faster Management of Pain in Prehospital Scenario; Its Safety and Comparative Efficacy in Animal Models

Intranasal Nalbuphine Formulation for Faster Management of Pain in Prehospital Scenario; Its Safety and Comparative Efficacy in Animal Models

Effect of polymer ratio on the quality of a co-processed excipient of prosopis gum and crab shell chitosan

Ex-vivo evaluation of crab shell chitosan as absorption enhancer in ciprofloxacin tablet formulation

Contact Info

Product

Resources

About